TP53 and breast neoplasm: Somatic TP53mutations have been reported in more than 60% of BRCA1-BCs but in lower frequency inBRCA2 breast tumors (Crook et al.,1998; Manié et al.,2009; Network, 2012).Interestingly, a significant proportion of TP53 somatic mutationsare protein-truncating (nonsense and frameshift mutations), suggesting strongselection for p53 loss-of-function rather than missense hotspot mutations (Holstege et al., 2009).